Brinker Capital Investments’s VanEck Pharmaceutical ETF PPH Stock Holding History

Brinker Capital Investments’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.36M	Sell	21,563 -676	-3%	-$70K	0.02%	711
2026 Q1	$2.31M	Sell	22,239 -1,732	-7%	-$185K	0.02%	690
2025 Q4	$2.47M	Sell	23,971 -9,722	-29%	-$946K	0.02%	740
2025 Q3	$3.04M	Buy	33,693 +180	+0.5%	+$15.8K	0.02%	628
2025 Q2	$2.95M	Sell	33,513 -1,977	-6%	-$171K	0.03%	597
2025 Q1	$3.23M	Buy	35,490 +5,610	+19%	+$505K	0.03%	496
2024 Q4	$2.58M	Sell	29,880 -985	-3%	-$89.1K	0.03%	575
2024 Q3	$2.93M	Sell	30,865 -991	-3%	-$94.1K	0.03%	517
2024 Q2	$2.91M	Sell	31,856 -1,111	-3%	-$99.2K	0.03%	488
2024 Q1	$2.99M	Sell	32,967 -1,844	-5%	-$161K	0.03%	478
2023 Q4	$2.96M	Sell	34,811 -3,227	-8%	-$253K	0.03%	450
2023 Q3	$3.04M	Sell	38,038 -2,290	-6%	-$185K	0.04%	437
2023 Q2	$3.18M	Sell	40,328 -1,292	-3%	-$101K	0.03%	462
2023 Q1	$3.23M	Buy	+41,620	New	+$3.21M	0.04%	400
2021 Q2	–	Sell	-70,000	Closed	-$4.83M	–	1347
2021 Q1	$4.83M	Sell	70,000 -40,000	-36%	-$2.76M	0.07%	273
2020 Q4	$7.31M	Sell	110,000 -32,151	-23%	-$2.06M	0.11%	213
2020 Q3	$8.84M	Sell	142,151 -80,000	-36%	-$5.06M	0.15%	163
2020 Q2	$13.8M	Sell	222,151 -7,000	-3%	-$423K	0.58%	49
2020 Q1	$12.5M	Buy	229,151 +151	+0.1%	+$9.3K	0.57%	53
2019 Q4	$14.7M	Hold	229,000	–	–	0.49%	56
2019 Q3	$13.1M	Sell	229,000 -14,000	-6%	-$802K	0.45%	59
2019 Q2	$14.3M	Sell	243,000 -4,000	-2%	-$232K	0.45%	64
2019 Q1	$15M	Buy	247,000 +100,000	+68%	+$5.91M	0.48%	58
2018 Q4	$8.05M	Buy	+147,000	New	+$8.9M	0.28%	89
2018 Q3	–	Sell	-147,000	Closed	-$8.67M	–	685
2018 Q2	$8.67M	Hold	147,000	–	–	0.28%	84
2018 Q1	$8.35M	Buy	147,000 +3,000	+2%	+$179K	0.27%	86
2017 Q4	$8.54M	Buy	144,000 +122,000	+555%	+$7M	0.28%	80
2017 Q3	$1.27M	Buy	+22,000	New	+$1.25M	0.05%	190

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Brinker Capital Investments's PPH Position: Q2 2026 in Review

Brinker Capital Investments reduced its VanEck Pharmaceutical ETF (PPH) stake by 3% in Q2 2026, selling an estimated $70K and leaving 21,563 shares worth $2.36M. The position accounts for 0.02% of the portfolio, ranked #711.

Brinker Capital Investments first reported a position in PPH in Q3 2017 and has held it in 28 quarters since. The position peaked at $15M in Q1 2019. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Brinker Capital Investments held 21,563 shares of VanEck Pharmaceutical ETF worth $2.36M as of Q2 2026.
Brinker Capital Investments sold 676 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $70K.
VanEck Pharmaceutical ETF made up 0.02% of Brinker Capital Investments's portfolio in Q2 2026, its #711 holding.
Brinker Capital Investments first reported a position in VanEck Pharmaceutical ETF in Q3 2017 and has held it in 28 quarters since.
Brinker Capital Investments's VanEck Pharmaceutical ETF position peaked at $15M in Q1 2019.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.